March 12, 2020

Dr. Edward Yardeni
516-972-7683
eyardeni@yardeni.com

Mali Quintana
480-664-1333
aquintana@yardeni.com

Please visit our sites at
www.yardeni.com
blog.yardeni.com
<table>
<thead>
<tr>
<th>Table Of Contents</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>S&amp;P 500 Health Care</td>
<td>1</td>
</tr>
<tr>
<td>Earnings</td>
<td>2</td>
</tr>
<tr>
<td>Revenues &amp; Margins</td>
<td>3</td>
</tr>
<tr>
<td>Earnings Growth &amp; Valuation</td>
<td>4</td>
</tr>
<tr>
<td>S&amp;P 500: Health Care</td>
<td>5</td>
</tr>
<tr>
<td>S&amp;P 500: Health Care (cont)</td>
<td>6</td>
</tr>
<tr>
<td>S&amp;P 500/400/600 Health Care YTD</td>
<td>7-8</td>
</tr>
<tr>
<td>Health Care</td>
<td>9-16</td>
</tr>
</tbody>
</table>
S&P 500 Health Care

Figure 1.

S&P 500 HEALTH CARE STOCK PRICE INDEX*

---

200-day moving average.

* Ratio scale.

Source: Standard & Poor’s and Haver Analytics.

Figure 2.

S&P 500 HEALTH CARE (as a ratio of S&P 500)

---

Note: Shaded areas denote recessions according to the National Bureau of Economic Research. Monthly through December 1990, then weekly. Monthly data an average of Hospital Management, Medical Products, and Pharmaceutical industry ratios.

Source: Standard & Poor’s Corporation.

---

Page 1 / March 12, 2020 / Analyst’s Handbook: Health Care

Yardeni Research, Inc.

www.yardeni.com
Figure 3.

*S&P 500 HEALTH CARE OPERATING EARNINGS PER SHARE*
(Analysts’ average forecasts, ratio scale)

Consensus Forecasts
- Annual estimates
- Forward earnings*

*Time-weighted average of consensus estimates for current year and next year. Monthly through December 2005, then weekly.
Source: I/B/E/S data by Refinitiv.

Figure 4.

*S&P 500 HEALTH CARE NET EARNINGS REVISIONS*

*Three-month moving average of the number of forward earnings estimates up less number of estimates down, expressed as a percentage of the total number of forward earnings estimates.
Source: I/B/E/S data by Refinitiv.
Figure 5.

S&P 500 HEALTH CARE REVENUES PER SHARE
(analysts' average forecasts, ratio scale)

Consensus Forecasts
- Annual estimates
- Forward revenues*


Figure 6.

S&P 500 HEALTH CARE PROJECTED PROFIT MARGIN
(using analysts' average earnings and revenues forecasts)

Consensus Forecasts
- Annual estimates
- Forward profit margin* (10.5)

**Figure 7.**

S&P 500 HEALTH CARE STRG, STEG, & LTEG (percent)

- LTEG* (9.6)
- STEG* (8.4)
- STRG* (7.5)

*S* STEG is year-ahead forward consensus expected short-term earnings growth. STRG is year-ahead forward consensus expected short-term revenue growth. LTEG is five-year consensus expected long-term earnings growth.

Monthly data through 2005, weekly thereafter.

Source: I/B/E/S data by Refinitiv.

**Figure 8.**

S&P 500 HEALTH CARE VALUATION

- Forward P/E* (15.4)
- Relative P/E** (0.9)
- PEG Ratio*** (1.6)

* Price divided by 12-month forward consensus expected operating earnings per share.

** Sector or industry forward P/E relative to S&P 500 forward P/E.

*** Sector or industry forward P/E relative to sector or industry consensus 5-year LTEG forecast.

Source: I/B/E/S data by Refinitiv.
Figure 9.

S&P 500 HEALTH CARE

S&P 500 HEALTH CARE EQUIPMENT
(ABT BAX BCR RDX BSX EW HOLX ISRG MDT RMD STJ SYK VAR ZMH)

S&P 500 BIOTECHNOLOGY
(ABBV ALXN AMGN BIB CELG GILD REGN VRTX)

S&P 500 HEALTH CARE FACILITIES
(HCA UHS)

S&P 500 HEALTH CARE DISTRIBUTORS
(ABC CAH HSIC MCK PDCO)

S&P 500 HEALTH CARE SERVICES
(DGX DVA ESRX LH)

Source: Standard & Poor’s Corporation.
Figure 10.

S&P 500 MANAGED HEALTH CARE
(AET ANTM CI CNC HUM UNH)

S&P 500 HEALTH CARE TECHNOLOGY
(CERN)

S&P 500 PHARMACEUTICALS
(AGN BMY ENDP JNJ LLY MRK MYL PFE PRGO ZTS)

S&P 500 LIFE SCIENCES TOOLS & SERVICES
(A ILMN PKI Q TMO WAT)

Source: Standard and Poor’s Corporation.

200-day moving average

yardeni.com
Figure 4.
S&P 500/400/600 Health Care YTD

Source: Standard & Poor's.
Figure 5. S&P 500/400/600 Health Care YTD

S&P 500 LargeCap

S&P 400 MidCap

S&P 600 SmallCap

Managed Health Care

Pharmaceuticals

Source: Standard & Poor’s.
Figure 13.

S&P HEALTH CARE

Source: Standard & Poor’s Corporation.

Figure 14.

S&P HEALTH CARE BIOTECHNOLOGY

Source: Standard & Poor’s Corporation.
Figure 15.

S&P HEALTH CARE DISTRIBUTORS

S&P 500 (488)
S&P 400 (172)
S&P 600 (113)

Source: Standard & Poor’s Corporation.

Figure 16.

S&P HEALTH CARE EQUIPMENT

S&P 500 (1462)
S&P 400 (2171)
S&P 600 (4632)

Source: Standard & Poor’s Corporation.
Source: Standard & Poor’s Corporation.
Figure 20.

S&P HEALTH CARE
(yearly percent change)

Source: Standard & Poor’s Corporation.

Figure 21.

S&P HEALTH CARE BIOTECHNOLOGY
(yearly percent change)

Source: Standard & Poor’s Corporation.
Figure 22.

S&P HEALTH CARE DISTRIBUTORS
(yearly percent change)

S&P 500 (5.5)
S&P 400 (-44.4)
S&P 600 (13.9)

Source: Standard & Poor’s Corporation.

Figure 23.

S&P HEALTH CARE EQUIPMENT
(yearly percent change)

S&P 500 (-1.9)
S&P 400 (-3.2)
S&P 600 (-17.8)

Source: Standard & Poor’s Corporation.
Figure 24.
S&P HEALTH CARE SERVICES
(yearly percent change)

Source: Standard & Poor’s Corporation.

Figure 25.
S&P MANAGED HEALTH CARE
(yearly percent change)

Source: Standard & Poor’s Corporation.
Figure 26.

S&P HEALTH CARE PHARMACEUTICALS
( yearly percent change)

Source: Standard & Poor’s Corporation.
Copyright (c) Yardeni Research, Inc. 2020. All rights reserved. The information
contained herein has been obtained from sources believed to be reliable, but is not
necessarily complete and its accuracy cannot be guaranteed. No representation or
warranty, express or implied, is made as to the fairness, accuracy, completeness, or
correctness of the information and opinions contained herein. The views and the other
information provided are subject to change without notice. All reports and podcasts posted on
www.yardeni.com, blog.yardeni.com, and YRI’s Apps are issued
without regard to the specific investment objectives, financial situation, or particular needs
of any specific recipient and are not to be construed as a solicitation or an offer to buy or sell
any securities or related financial instruments. Past performance is not necessarily a guide
to future results. Company fundamentals and earnings may be mentioned occasionally, but
should not be construed as a recommendation to buy, sell, or hold the company’s stock.
Predictions, forecasts, and estimates for any and all markets should not be construed as
recommendations to buy, sell, or hold any security--including mutual funds, futures
contracts, and exchange traded funds, or any similar instruments.

The text, images, and other materials contained or displayed on any Yardeni Research, Inc.
product, service, report, email or website are proprietary to Yardeni Research, Inc. and
constitute valuable intellectual property. No material from any part of www.yardeni.com,
blog.yardeni.com, and YRI’s Apps may be downloaded, transmitted,
broadcast, transferred, assigned, reproduced or in any other way used or otherwise
disseminated in any form to any person or entity, without the explicit written consent of
Yardeni Research, Inc. All unauthorized reproduction or other use of material from Yardeni
Research, Inc. shall be deemed willful infringement(s) of this copyright and other proprietary
and intellectual property rights, including but not limited to, rights of privacy. Yardeni
Research, Inc. expressly reserves all rights in connection with its intellectual property,
including without limitation the right to block the transfer of its products and services and/or
to track usage thereof, through electronic tracking technology, and all other lawful means,
now known or hereafter devised. Yardeni Research, Inc. reserves the right, without further
notice, to pursue to the fullest extent allowed by the law any and all criminal and civil
remedies for the violation of its rights.

The recipient should check any email and any attachments for the presence of viruses.
Yardeni Research, Inc. accepts no liability for any damage caused by any virus transmitted
by this company’s emails, website, blog and Apps. Additional information available on
request.